#Taiwan #Zhubei #Charles River #Locus Cell #APAC Summit

Introduction

On March 11, 2026, during the prestigious APAC Biomanufacturing Leadership Summit in Singapore, Locus Cell Co., Ltd. signed a Memorandum of Understanding (MoU) with Charles River Laboratories. This pivotal agreement marks a significant collaboration in the field of cell and gene therapy, highlighting the commitment of both organizations to enhance the biopharmaceutical manufacturing landscape in the Asia-Pacific region.

Background of Locus Cell

Locus Cell is a Contract Development and Manufacturing Organization (CDMO) based in Taiwan, specializing in cell and gene therapy (CGT). With a dedicated focus on this burgeoning field, the company is constructing an advanced digital-native smart cell factory in Zhubei, Taiwan. This facility is designed to incorporate AIoT systems and digital manufacturing technologies, ensuring compliance with PIC/S GMP standards. The factory will cater to the increasing demands of the CGT sector, producing therapies that have the potential to transform patient outcomes.

Charles River's Role

Founded as a global contract research organization (CRO), Charles River Laboratories provides essential support in drug development and biologics testing solutions. Their extensive experience and resources have been instrumental in the success of numerous FDA-approved therapeutics, positioning them as a key player in advancing biomedical innovation. The collaboration with Locus Cell is expected to leverage Charles River's expertise to enhance the quality and efficacy of therapy production.

Summit Highlights

The APAC Biomanufacturing Leadership Summit served as a significant platform for dialogue among industry leaders, regulatory experts, and investors. The overarching theme of the summit was "Shaping the Region's Bioproduction Landscape – From Scale-Up Innovation to Quality Compliance." The discussions focused on improving regional manufacturing capabilities, accelerating innovation, and maintaining alignment with global regulatory standards.

Details of the MoU

The MoU establishes a framework for Locus Cell and Charles River to explore opportunities for collaboration in a variety of areas, including CMC support, analytical testing, and technical development services specifically for advanced therapy developers throughout Taiwan and the broader Asia-Pacific area. This alliance aims to strengthen the manufacturing landscape in the region, promoting the development of cutting-edge therapies that could benefit patients worldwide.

Strategic Importance of Collaboration

CEO Sean Chang of Locus Cell emphasized the importance of this collaboration, stating, "This MoU reflects our shared commitment to strengthening collaboration in advanced therapies." By aligning their resources and expertise, both organizations will focus on evaluating integration opportunities and mutual customer referral strategies. The synergy of Locus Cell's dedicated CGT manufacturing capabilities, including CART, iPSC, and immune cell platforms, combined with Charles River’s robust testing and analytical development services encapsulates a promising avenue for advancing therapy production.

Looking Ahead

As Taiwan continues to establish a supportive regulatory framework for regenerative medicine, this partnership exemplifies the potential for international collaboration in advancing healthcare solutions. Locus Cell invites global partners to engage in this transformative journey, signaling a bright future for cell and gene therapy manufacturing in the region.

Conclusion

This collaboration between Locus Cell and Charles River symbolizes a significant step forward in the realm of biomanufacturing and advanced therapies. As both organizations embark on this journey together, the future of cell and gene therapies in the Asia-Pacific region looks brighter than ever, promising innovative solutions tailored to meet the demands of modern healthcare.

Source: Locus Cell Co., Ltd.